Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery

被引:78
作者
Balimane, PV [1 ]
Patel, K [1 ]
Marino, A [1 ]
Chong, SH [1 ]
机构
[1] Bristol Myers Squibb, Pharmaceut Candidate Optimazat, Princeton, NJ USA
关键词
permeability; efflux transporter; Caco-2; high throughput; P-glycoprotein; inhibitor; substrate;
D O I
10.1016/j.ejpb.2004.02.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The use of Caco-2 cells for screening of discovery compounds for their permeability characteristics and P-glycoprotein interactions is well established and used routinely in pharmaceutical industries world-wide. The screening model involves growing cells on 12 or 24 well transwell format. In this manuscript, we report the use of Caco-2 cells grown on 96 well transwell plates for screening compounds for their potential to interact with P-gp. Bi-directionality studies were performed with known P-gp substrates such as saquinavir, indinavir, vinblastine, vincristine, verapamil, digoxin and taxol. P-gp inhibition studies were also conducted using radiolabeled digoxin as the probe. The results demonstrated, that P-gp substrates had efflux ratios (P-c (B to A)/P-c (A to B)) in the 96 well format that were comparable to the ratios seen in 12 and 24 well format. Inhibition of digoxin efflux transport in presence of the test compounds (P-gp substrates) demonstrated that 96 well cells express adequate amounts of efflux transporters and perform as well as the 12 and 24 well Caco-2 cells. Thus, the 96 well Caco-2 cell set-up presents a higher throughput permeability model capable of identifying compounds that interact with P-gp and has the potential to significantly increase the efficiency of P-gp screening in early drug discovery. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:99 / 105
页数:7
相关论文
共 20 条
[1]   Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein [J].
Adachi, Y ;
Suzuki, H ;
Sugiyama, Y .
PHARMACEUTICAL RESEARCH, 2001, 18 (12) :1660-1668
[2]  
ARTURSSON P, 1991, CRIT REV THER DRUG, V8, P305
[3]   Current methodologies used for evaluation of intestinal permeability and absorption [J].
Balimane, PV ;
Chong, SH ;
Morrison, RA .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2000, 44 (01) :301-312
[4]   In vitro permeability through Caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system [J].
Chong, SH ;
Dando, SA ;
Soucek, KM ;
Morrison, RA .
PHARMACEUTICAL RESEARCH, 1996, 13 (01) :120-123
[5]   Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates [J].
Ekins, S ;
Kim, RB ;
Leake, BF ;
Dantzig, AH ;
Schuetz, EG ;
Lan, LB ;
Yasuda, K ;
Shepard, RL ;
Winter, MA ;
Schuetz, JD ;
Wikel, JH ;
Wrighton, SA .
MOLECULAR PHARMACOLOGY, 2002, 61 (05) :974-981
[6]   IN-VITRO SYSTEMS FOR STUDYING INTESTINAL DRUG ABSORPTION [J].
HILLGREN, KM ;
KATO, A ;
BORCHARDT, RT .
MEDICINAL RESEARCH REVIEWS, 1995, 15 (02) :83-109
[7]   The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil [J].
Johnson, BM ;
Charman, WN ;
Porter, CJH .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2001, 53 (12) :1611-1619
[8]  
Kim RB, 1999, PHARMACEUT RES, V16, P408
[9]   Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin [J].
Kovarik, JM ;
Rigaudy, L ;
Guerret, M ;
Gerbeau, C ;
Rost, KL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (04) :391-400
[10]   INTERACTION BETWEEN QUINIDINE AND DIGOXIN [J].
LEAHEY, EB ;
REIFFEL, JA ;
DRUSIN, RE ;
HEISSENBUTTEL, RH ;
LOVEJOY, WP ;
BIGGER, JT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1978, 240 (06) :533-534